Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **measles virus fusion protein (F)**, **hemagglutinin (H)**, and **nucleoprotein (N)** are three essential proteins encoded by the measles virus, a member of the Paramyxoviridae family. The **hemagglutinin (H) protein** is a viral glycoprotein that mediates attachment to host cell receptors, including SLAMF1 (CD150), Nectin-4 (PVRL4), and sometimes CD46, determining key aspects of cell tropism and initiating viral entry[4][7]. Upon H binding to a cellular receptor, the **fusion (F) protein**, a class I viral fusion glycoprotein, is triggered to mediate the merger of the viral envelope with the host membrane, enabling viral genome entry and, in some cases, syncytia formation (cell-cell fusion)[1][2][4]. The **nucleoprotein (N)** encapsidates the viral RNA and, together with the phosphoprotein (P) and RNA-dependent RNA polymerase (L), forms the ribonucleoprotein complex, critical for RNA synthesis and genome protection[4][5][10]. All three proteins are core immunological targets for vaccine design and serodiagnostics, and could theoretically be targeted by antiviral drugs or neutralizing antibodies[6][7]. While no direct-acting small molecule inhibitors are currently licensed, neutralizing antibodies against H or F are a focus of research. Safety concerns are inherent to live vaccine strains (attenuation, neurovirulence), but these proteins themselves constitute well-established, clinically validated targets[6][7].
For fusion/entry inhibitors: block F-mediated membrane fusion, or H-mediated receptor attachment. For neutralizing antibodies: bind to H or F to prevent viral entry
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Measles virus fusion protein, hemagglutinin, and nucleoprotein (MeV F, H, and N).